Abstract
Background:Triple-negative breast(TNBC) cancer is a molecular subtype of breast cancer with poor prognosis and did not get approved targeted therapy till now. In the last years, metronomic chemotherapy (mCTH) was investigated to improve treatment outcomes in TNBC patients both in early and metastatic setting due to its anti-angiogenic and immune-stimulatory mechanisms. The aim of this study is to evaluate the efficacy and safety of extended adjuvant chemotherapy with metronomic docetaxel for patients with operable TNBC. Methods:31 women with clinically and pathologically proved operable TNBC, either node-negative or node-positive with tumor size ≥ 0,5 cm were enrolled after finishing the primary standard of care treatment. The patients were subjected to extended adjuvant therapy for 6 months with metronomic low dose docetaxel with starting dose of 15mg/m2 in weekly bases for 4 weeks then the dose was escalated to 20 mg/m2 once per week if there were no side effects. Results:After a median follow up of 36 months (range 6-52), 24 patients (77.4%) were still alive. During the period of follow-up, 12 patients (38.7%) showed disease relapse and 19(61.3%) cases remain free of the disease. The estimated mean of DFS in our study was 38.26 months (95%CI; 31.87 – 44.65) with 2 and 3 years DFS rate of 70.5 % and 56.4% respectively while the estimated mean of OS was 43.75 months (95% CI; 38.35 – 49.16) with 2 and 3 years OS rates 83.3% and 78.1% respectively, Generally the treatment was tolerated with mild to moderate hematological and non hematological adverse events, all are grade 1,2 and treatment-related deaths were not observed. Conclusion:Extended adjuvant treatment for 6 months with metronomic docetaxel after the primary standard of care therapy was tolerated and has an encouraging survival benefit in patients with operable TNBC and these results need further evaluation in randomized control studies.
Highlights
Breast cancer (BC) is a highly heterogeneous disease at both clinical and molecular settings, Triple-negative breast cancer (TNBC) accounts for around 20% of the all BC molecular subtypes and has a very worse prognosis with short overall survival (Fragomeni et al, 2018)
A novel approach to improve disease-free survival and subsequent overall survival of TNBC patients is the use of extended adjuvant treatment with metronomic chemotherapy
The main objective of metronomic chemotherapy (mCTH) is to achieve a comparable or good efficacy along with tolerability and safety compared to standard conventional chemotherapy, it is considered by some authors as an attractive novel approaches with additional anti-angiogenic effects with lesser toxicities compared to the standard chemotherapy (Banys-Paluchowski et al, 2016)
Summary
Breast cancer (BC) is a highly heterogeneous disease at both clinical and molecular settings, Triple-negative breast cancer (TNBC) accounts for around 20% of the all BC molecular subtypes and has a very worse prognosis with short overall survival (Fragomeni et al, 2018). A novel approach to improve disease-free survival and subsequent overall survival of TNBC patients is the use of extended adjuvant treatment with metronomic chemotherapy (mCTH). The aim of this study is to evaluate the efficacy and safety of extended adjuvant chemotherapy with metronomic docetaxel for patients with operable TNBC. Conclusion: Extended adjuvant treatment for 6 months with metronomic docetaxel after the primary standard of care therapy was tolerated and has an encouraging survival benefit in patients with operable TNBC and these results need further evaluation in randomized control studies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
